pentobarbital will lower the extent or influence of ethotoin by impacting hepatic enzyme CYP2C9/ten metabolism. Use Caution/Check.
After stopping a CYP3A4 inducer, since the effects on the inducer drop, the fentanyl plasma focus will maximize which could enhance or lengthen both the therapeutic and adverse effects.
pentobarbital will reduce the extent or outcome of almotriptan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.
pentobarbital will lower the extent or outcome of finasteride by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Unidentified.
pentobarbital will decrease the extent or impact of levamlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital decreases levels of panobinostat by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inducers can decrease panobinostat levels by ~70% and produce cure failure.
pentobarbital will lessen the extent or influence of amlodipine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.
pentobarbital will lower the level or effect of cilostazol by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
pentobarbital decreases amounts of ponatinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid unless the coadministration outweighs the possible risk of ponatinib underexposure; observe for signs of lowered efficacy.
pentobarbital will minimize the extent or influence of dexamethasone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.
Watch Closely (1)pentobarbital will minimize the level or influence of fentanyl transdermal by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Carefully. Coadministration of fentanyl with CYP3A4 inducers could lead to some minimize in fentanyl plasma concentrations, insufficient efficacy or, possibly, progress of the withdrawal syndrome within a client who may have created physical dependence to fentanyl. Soon after stopping a CYP3A4 inducer, since the effects with the inducer decrease, the fentanyl plasma concentration will enhance which could raise or extend equally the therapeutic and adverse effects.
buprenorphine subdermal implant and pentobarbital the two maximize sedation. Prevent or Use Alternate Drug. Limit use to clients for whom alternate cure solutions are inadequate
Contraindicated (1)pentobarbital will minimize the level or influence of lonafarnib by affecting hepatic/intestinal get more info enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib is usually a sensitive CYP3A4 substrate. Coadministration with solid or moderate CYP3A4 inducers is contraindicated.
pentobarbital will lessen the extent or outcome of glecaprevir/pibrentasvir by influencing hepatic/intestinal enzyme CYP3A4 metabolism.